AstraZeneca announced Friday that their investigational breathing medication demonstrated significant success in decreasing severe episodes for patients suffering from chronic obstructive pulmonary disease during two major advanced clinical trials.
The pharmaceutical company reported that tozorakimab achieved its primary objective in both studies, successfully lowering the yearly occurrence of moderate-to-severe COPD episodes compared to inactive treatment in the main study group of previous smokers and across all participants.
Both current and past tobacco users with different degrees of respiratory damage and varying white blood cell levels participated in the research, according to the company.
COPD represents a long-term medical condition that limits air passage and creates difficulty breathing. Although cigarette smoking serves as the primary cause, exposure to vapors, industrial chemicals, and workplace particles can also trigger the disease’s development.
The experimental medication falls under the monoclonal antibody treatment category, functioning by mimicking natural immune responses and blocking interleukin-33, a protein that contributes to inflammatory processes.
According to AstraZeneca, their medication could potentially decrease inflammation and break the harmful pattern of mucus problems that may intensify COPD symptoms in patients. The World Health Organization ranks this respiratory disease as the fourth most common cause of death globally.
The pharmaceutical company plans to share comprehensive results from both clinical trials at a future medical conference.
This development follows AstraZeneca’s September announcement that their asthma medication Fasenra did not successfully decrease symptom worsening in COPD patients during a different advanced study.
